Elevage Medical Technologies

About Elevage Medical Technologies

Elevage Medical Technologies operates as a specialized investment firm, established in May 2023 as a portfolio company of Patient Square Capital. The firm was launched with an initial capital commitment of $300 million from Patient Square Capital to address a funding gap for growth-stage medical device companies. Elevage's business model centers on providing both capital investment and strategic operational support to its portfolio companies, focusing on accelerating the approval and commercialization of their products.

The company is led by CEO Dr. Evan Melrose, who brings over two decades of experience in healthcare across clinical, investment, and operational functions. His background includes roles as the Founding Managing Director at venture capital firms Spindletop Capital and PTV Sciences, along with board positions at companies like IntersectENT and Bioventus. Dr. Melrose holds an M.D. from Indiana University School of Medicine and an MBA from The Wharton School, blending clinical knowledge with financial expertise.

Elevage targets growth-stage medical technology companies that have developed devices capable of improving patient health outcomes and quality of life. The firm's strategy involves partnering with a select number of companies, typically between five and ten over a couple of years, that are on the verge of significant market impact. A key focus is on technologies that support the shift towards regenerative medicine and minimally invasive surgery. To be considered for partnership, companies must demonstrate their product's ability to enhance patient health while also lowering costs for healthcare providers. Its portfolio includes investments in companies like Elucid, a medical technology company with an AI-powered imaging analysis platform for cardiovascular disease, and SetPoint Medical.